Add to ORKGThe burden of hypogammaglobulinaemia following rituximab (RTX) treatment in rheumatic diseases has not been fully elucidated yet. Our aim was to evaluate the frequency and predictors of hypogammaglobulinaemia in patients affected by ANCA-associated vasculitis (AAV) and connective tissue diseases (CTD)
Rituximab, an anti-CD20 chimeric antibody, is the first monoclonal agent to be used in the therapy o...
To assess the impact of immunosuppressive therapy with cyclophosphamide (CYC) and rituximab (RTX) on...
Rituximab (RTX), a chimeric monoclonal antibody targeting CD20-positive cells, is a valuable treatme...
OBJECTIVES: Rituximab has become the cornerstone of induction treatment in ANCA-associated vasculiti...
Rituximab is a B cell depleting monoclonal antibody used to treat lymphoma and autoimmune disease. H...
Rituximab is a B cell depleting monoclonal antibody used to treat lymphoma and autoimmune disease. H...
Background: Rituximab (RTX) is an anti-CD20 chimeric monoclonal antibody recommended as off- label t...
Objective: To evaluate the characteristics of patients with autoimmune disease with hypogammaglobuli...
BACKGROUND: Rituximab (RTX; anti-CD20 mAb) is a treatment option in children with refractory immune ...
Rituximab (RTX) is a monoclonal antibody against CD20, commonly used in the treatment of hematologic...
BACKGROUND: Rituximab (RTX; anti-CD20 mAb) is a treatment option in children with refractory immune ...
Objectives. To study the determinants of the pharmacokinetics (PK) of rituximab (RTX) in patients wi...
Objective: To evaluate predictors of serious infection events (SIEs) during rituximab (RTX) therapy ...
We describe a case of a 3-year-old male toddler with a history of severe and refractory warm antibod...
Background. 29 GPA patients from the Northern Norway vasculitis disease registry received rituximab ...
Rituximab, an anti-CD20 chimeric antibody, is the first monoclonal agent to be used in the therapy o...
To assess the impact of immunosuppressive therapy with cyclophosphamide (CYC) and rituximab (RTX) on...
Rituximab (RTX), a chimeric monoclonal antibody targeting CD20-positive cells, is a valuable treatme...
OBJECTIVES: Rituximab has become the cornerstone of induction treatment in ANCA-associated vasculiti...
Rituximab is a B cell depleting monoclonal antibody used to treat lymphoma and autoimmune disease. H...
Rituximab is a B cell depleting monoclonal antibody used to treat lymphoma and autoimmune disease. H...
Background: Rituximab (RTX) is an anti-CD20 chimeric monoclonal antibody recommended as off- label t...
Objective: To evaluate the characteristics of patients with autoimmune disease with hypogammaglobuli...
BACKGROUND: Rituximab (RTX; anti-CD20 mAb) is a treatment option in children with refractory immune ...
Rituximab (RTX) is a monoclonal antibody against CD20, commonly used in the treatment of hematologic...
BACKGROUND: Rituximab (RTX; anti-CD20 mAb) is a treatment option in children with refractory immune ...
Objectives. To study the determinants of the pharmacokinetics (PK) of rituximab (RTX) in patients wi...
Objective: To evaluate predictors of serious infection events (SIEs) during rituximab (RTX) therapy ...
We describe a case of a 3-year-old male toddler with a history of severe and refractory warm antibod...
Background. 29 GPA patients from the Northern Norway vasculitis disease registry received rituximab ...
Rituximab, an anti-CD20 chimeric antibody, is the first monoclonal agent to be used in the therapy o...
To assess the impact of immunosuppressive therapy with cyclophosphamide (CYC) and rituximab (RTX) on...
Rituximab (RTX), a chimeric monoclonal antibody targeting CD20-positive cells, is a valuable treatme...